

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Peijia Medical Limited

沛嘉醫療有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9996)

VOLUNTARY ANNOUNCEMENT UNAUDITED OPERATING STATISTICS FOR THE SIX MONTHS ENDED JUNE 30, 2026

This announcement is made by Peijia Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and product development progress of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce certain unaudited operating statistics of the Group for the six months ended June 30, 2026 (the “**Reporting Period**”), and the comparative figures as set out below.

	For the period from		
	January 1 to June 30,		
	2026	2025	Change
	RMB' million	RMB' million	%
Revenue	Approximately 415.0–435.0	353.4	Approximately 17.4–23.1

The Group’s solid revenue growth was primarily attributable to: (i) the continued expansion of the Transcatheter Valve Therapeutic Business, driven by the successful commercialization of new indication products, which enabled the Group to capture the new on-label aortic regurgitation (“**AR**”) market opportunity by leveraging the Group’s established transcatheter aortic valve replacement (“**TAVR**”) commercialization capabilities; and (ii) the continued growth of the Group’s Neurointerventional Business, driven by the sustained market penetration of its self-developed products and the expansion of its product portfolio through strategic collaborations.

In respect of the Transcatheter Valve Therapeutic Business, the Group continued to consolidate its leading position in China's transfemoral TAVR market. As at June 30, 2026, the Group's TAVR product portfolio had expanded its hospital coverage to over 850 hospitals across Greater China, representing an increase of approximately 70 hospitals as compared with December 31, 2025. During the Reporting Period, total TAVR implantations, including implantations of both aortic stenosis ("AS") and AR indication products, reached approximately 2,830 units, representing a significant increase of approximately 36.5% in implantation volume as compared with the six months ended June 30, 2025.

The growth of the Transcatheter Valve Therapeutic Business was primarily driven by the successful commercialization of TaurusTrio® Transcatheter Aortic Valve System, the Group's TAVR system designed for the treatment of AR. Leveraging the Group's extensive experience and established commercial infrastructure accumulated through years of TAVR commercialization in the AS market, TaurusTrio® achieved rapid market adoption following its launch. As a novel solution addressing the unmet clinical needs in AR treatment, TaurusTrio® received broad market recognition, supported by its product design advantages, safety profile and standardized procedural approach, which expedited clinical adoption. With over 660 implantations performed in the Chinese mainland during the Reporting Period, TaurusTrio® demonstrated strong clinical acceptance and commercialization potential. Meanwhile, leveraging the differentiated performance of TaurusMax®, the Group's 3D-steerable TAVR system, the Group's AS indication product portfolio maintained growth amid an increasingly competitive market environment.

In respect of the Neurointerventional Business, benefiting from the integrated model of self-developed innovation and strategic partnerships, the Group continued to expand its product portfolio and enhance its market competitiveness. The Group's proprietary products, including Syphonet® Stent Retriever, Fastunnel® Delivery Balloon Dilatation Catheter and DCwire® Micro Guidewire, continued to gain market recognition, supported by their differentiated designs and superior performance, contributing to sustained market penetration and revenue growth. Meanwhile, through strategic collaborations, the Group further expanded its Neurointerventional Business with strategically partnered products, including YonFlow® Flow Diverting Stent and QIDA® Disposable Neuro Introducer Sheath, which achieved commercial scale-up during the Reporting Period and contributed additional revenue growth.

As at the date of this announcement, the Company is still in the process of preparing and finalizing the interim results of the Group for the Reporting Period. The above operating information is preliminary unaudited information that has not been reviewed, confirmed or audited by the auditors of the Company, nor reviewed by the audit committee of the Board, and is provided for investors' reference only and it shall not be taken as a measure or

indication of the Group's future financial performance. Shareholders and potential investors are advised to read carefully the announcement of the Company in relation to the results of the Group for the Reporting Period, which is expected to be published in August 2026 in accordance with the requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE CAUTION WHEN DEALING IN THE SHARES OF THE COMPANY.

By order of the Board
Peijia Medical Limited
Dr. Yi ZHANG
Chairman and Executive Director

Hong Kong, August 7, 2026

As at the date of this announcement, the Board comprises Dr. Yi ZHANG, Mrs. Ping Ye ZHANG and Ms. Hong YE as executive Directors, Mr. Jifeng GUAN, Mr. Fei CHEN and Mr. Jun YANG as non-executive Directors, and Dr. Stephen Newman OESTERLE, Mr. Robert Ralph PARKS, Mr. Wai Ming YIP and Mr. Huacheng WEI as independent non-executive Directors.